Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T George

Showing results (661-670 of 771) with videos related to

Pageof 78
Sort By:
Transplant Immunology|December 2, 2006
Knockdown of mouse VCAM-1 by vector-based siRNAA K M Shamsul Alam, Oliver Florey, Michele Weber, et al.
Diabetes, Obesity & Metabolism|February 8, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOMESubodh Verma, Qiuhe Ji, Deepak L Bhatt, et al.
Arthritis and Rheumatism|September 29, 2011
Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritisPanagiotis Kamperidis, Tahereh Kamalati, Mathieu Ferrari, et al.
Circulation. Cardiovascular Imaging|October 8, 2009
Adenosine stress 64- and 256-row detector computed tomography angiography and perfusion imaging: a pilot study evaluating the transmural extent of perfusion abnormalities to predict atherosclerosis causing myocardial ischemiaRichard T George, Armin Arbab-Zadeh, Julie M Miller, et al.
Journal of the American Heart Association|June 14, 2021
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol TransportRichard T George, Liron Abuhatzira, Susan M Stoughton, et al.
European Journal of Heart Failure|December 11, 2019
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialMichael Böhm, Jonathan Slawik, Martina Brueckmann, et al.
Alcoholism, Clinical and Experimental Research|January 13, 2015
Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patientsPrimavera A Spagnolo, Vijay A Ramchandani, Melanie L Schwandt, et al.
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.
Alcoholism, Clinical and Experimental Research|September 8, 2011
The biometric measurement of alcohol consumptionLawrence D Snell, Vijay A Ramchandani, Laura Saba, et al.
Frontiers in Immunology|July 9, 2026
Delving into the innate and adaptive immunity of camelids: a paradigm of interspecies adaptation and evolutionary innovationRemya Pg Ramesh, Avinash Premraj, Hadida Yasmin, et al.
Pageof 78

Showing results (661-670 of 771) with videos related to

Sort By:
Pageof 78
Transplant Immunology|December 2, 2006
Knockdown of mouse VCAM-1 by vector-based siRNAA K M Shamsul Alam, Oliver Florey, Michele Weber, et al.
Diabetes, Obesity & Metabolism|February 8, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOMESubodh Verma, Qiuhe Ji, Deepak L Bhatt, et al.
Arthritis and Rheumatism|September 29, 2011
Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritisPanagiotis Kamperidis, Tahereh Kamalati, Mathieu Ferrari, et al.
Circulation. Cardiovascular Imaging|October 8, 2009
Adenosine stress 64- and 256-row detector computed tomography angiography and perfusion imaging: a pilot study evaluating the transmural extent of perfusion abnormalities to predict atherosclerosis causing myocardial ischemiaRichard T George, Armin Arbab-Zadeh, Julie M Miller, et al.
Journal of the American Heart Association|June 14, 2021
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol TransportRichard T George, Liron Abuhatzira, Susan M Stoughton, et al.
European Journal of Heart Failure|December 11, 2019
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialMichael Böhm, Jonathan Slawik, Martina Brueckmann, et al.
Alcoholism, Clinical and Experimental Research|January 13, 2015
Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patientsPrimavera A Spagnolo, Vijay A Ramchandani, Melanie L Schwandt, et al.
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.
Alcoholism, Clinical and Experimental Research|September 8, 2011
The biometric measurement of alcohol consumptionLawrence D Snell, Vijay A Ramchandani, Laura Saba, et al.
Frontiers in Immunology|July 9, 2026
Delving into the innate and adaptive immunity of camelids: a paradigm of interspecies adaptation and evolutionary innovationRemya Pg Ramesh, Avinash Premraj, Hadida Yasmin, et al.
Pageof 78